All In Biotech

Drug Trial Radar · NCT01502774

Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients

Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 970 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

970

Actual

Start

Apr 2011

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
Hospices Civils de LyonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Infarct size is a major determinant of prognosis after Acute Myocardial Infarction (AMI). The investigators recently reported that cyclosporine A, when administered immediately prior to percutaneous coronary intervention (PCI), can significantly reduce infarct size in STEMI (ST Elevation acute Myocardial Infarction) patients. The objective of the present study is to determine whether cyclosporine can improve STEMI patient clinical outcome. Nine-hundred and seventy two patients with ST elevation MI will be entered into a multicentre, randomized, placebo-controlled, double-blinded study. They will receive one single injection of cyclosporine A (CicloMulsion, verum) or an equivalent volume of placebo prior to reperfusion therapy by PCI. The incidence of the combined endpoint (mortality, hospitalization for heart failure, left ventricular (LV) remodeling) will be assessed at one year and three years after treatment.

Conditions

  • ST Elevation Acute Myocardial Infarction

Interventions

  • Injection of CyclosporinDrug

    one single intravenous bolus injection of 2.5 mg/Kg

  • PlaceboDrug

    One single intravenous bolus injection of Placebo

  • EchocardiographyProcedure

    1 year after AMI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined incidence of [total mortality; hospitalization for heart failure; LV remodeling (increase of LV end-diastolic volume > 15%)]Time frame: at 1 year post-AMI

Locations

45 sites in 3 countries. Site status is shown where the registry gives one.

  • Algemeen Ziekenhuis Sint-Jan Brugge

    Bruges, Belgium

  • Chu Charleroi

    Charleroi, Belgium

  • Hôpital universitaire d'Anvers (UZA)

    Edegem, Belgium

  • CHU Mont-Godinne

    Yvoir, Belgium

  • Clinique ESQUIROL - SAINT-HILAIRE

    Agen, France

  • Centre Hospitalier du Pays D'Aix

    Aix-en-Provence, France

  • Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Centre Hospitalier d'Annecy

    Annecy, France

  • Hôpital Henri Duffaut

    Avignon, France

  • Clinique Lafourcade

    Bayonne, France

  • Centre Hospitalier Universitaire

    Brest, France

  • Hopital Louis Pradel, Hospices Civils de Lyon

    Bron, France

  • CHRU- Hôpital de la Côte de Nacre

    Caen, France

  • Centre Hospitalier General

    Chartres, France

  • CHU - Hôpital Gabriel Montpied

    Clermont-Ferrand, France

  • CH de Compiègne

    Compiègne, France

  • CH Henri MONDOR

    Créteil, France

  • Hôpital du Bocage

    Dijon, France

  • Hôpital A. MICHALLON - CHU

    Grenoble, France

  • Centre Hospitalier General

    Haguenau, France

  • CHRU - Hôpital Cardiologique Calmette

    Lille, France

  • Clinique de la Sauvegarde

    Lyon, France

  • Centre Hospitalier St Luc St Joseph

    Lyon, France

  • Institut Jacques Cartier

    Massy, France

  • CHU Arnaud de Villeneuve

    Montpellier, France

  • Clinique du Millénaire

    Montpellier, France

  • CHU de Mulhouse

    Mulhouse, France

  • Clinique du Diaconat

    Mulhouse, France

  • Hôpital Guillaume et René Laennec

    Nantes, France

  • CHU de Nîmes

    Nîmes, France

  • Polyclinique des Fleurs

    Ollioules, France

  • APHP Hôpital Bichat

    Paris, France

  • CH de Pau

    Pau, France

  • Hôpital Haut Lévêque

    Pessac, France

  • Hôpital Claude Galien

    Quincy-sous-Sénart, France

  • Hôpital Pontchaillou

    Rennes, France

  • Hôpital Charles NICOLLE

    Rouen, France

  • Hôpitaux Universitaires, Nouvel Hôpital Civil

    Strasbourg, France

  • Clinique de l'Ormeau - CCV des Pyrénées

    Tarbes, France

  • CHU de Rangueil

    Toulouse, France

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.